Daiichi Sankyo Head Apologizes For, Defends Buy Of India's Ranbaxy
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo's Takashi Shoda apologized for harming shareholder equity with the company's purchase of India's Ranbaxy Laboratories, but said he was confident the move would pay off in the medium to long term. The head of Daiichi Sankyo said in an interview the timing of the expensive buy just before the financial crisis and then a Ranbaxy plant encountering problems with the U.S. FDA caused him to make several management changes. Shoda stressed that now that Malvinder Singh has departed Ranbaxy, Shoda is overseeing Ranbaxy and is aware of its problems. Shoda also said he learned of Ranbaxy problems with the FDA before the deal was closed, but noted the United States accounted for only a quarter of the Indian company's total sales. (Click here for more
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Nominates Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.